Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Myocardial infarction leads to microvascular dysfunction with consecutively reduced coronary flow reserve, which persists after 4 months. Moreover, recent clinical trials have shown that a reduced coronary flow reserve is associated with adverse outcome in the future. Intracoronary infusion of bone marrow-derived progenitor cells lead to complete normalization of coronary blood flow, as demonstrated by the placebo-controlled, double-blind REPAIR-AMI trial, suggesting increased neovascularization by the infused cells . Therefore, the primary objective of the current trial is to improve coronary flow reserve in patients with NSTEMI by intracoronary infusion of autologous bone marrow-derived mononuclear progenitor cells, compared with a placebo group, in a double-blind way.
Critère d'inclusion
- Patients with acute coronary syndrome (NSTEMI) due to coronary artery disease